Johnson & Johnson's Stelara notched and FDA approval to treat ulcerative colitis—its second GI approval—in October. (Johnson & Johnson)
Stelara Company: Johnson & Johnson Used for: Plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis 2019 sales: $4.35 billion
Johnson & Johnson's stalwart immunology blockbuster Stelara has been a steady earner for years. But with some areas of its portfolio lagging behind, J&J is hoping that pushing Stelara into new markets can help overcome those stumbles—and keep Stelara generating significant sales for years to come.
Stelara could add around $800 million in sales to its 2019 haul of $4.35 billion, bringing its 2020 sales total to around $5.15 billion in 2020, according to EvaluatePharma.
Most of that growth will ultimately be tied to Stelara's FDA nod in October to treat ulcerative colitis—the med's first new approval in two years.